Synbiotic (probiotic and ginger extract) loaded floating beads: a novel therapeutic option in an experimental paradigm of gastric ulcer.
OBJECTIVE
This study investigated the use of a bioactive phytochemical, namely ginger extract (GE), for its antioxidant and antiulcer effects, and also for supporting probiotic growth and activity. Use of probiotics is limited in therapy because of their transience and inability to survive the adverse physiological conditions of the gastrointestinal tract. Packaging probiotics in a suitably designed pharmaceutical system with GE may facilitate their establishment in the stomach mucosa.


METHODS
A probiotic (Lactobacillus acidophilus) and GE were simultaneously and individually encapsulated/immobilized in alginate floating beads. The developed system was evaluated for diameter, buoyancy, entrapment, porosity, in-vitro viability/release and pharmacodynamics in a cold restraint stress induced gastric ulcer model in rats.


RESULTS
The developed floating beads stayed in the stomach for more than 10 h and both agents were released slowly and over a prolonged period from these beads. Significant and promising results were obtained for the combination (synbiotic) system in terms of ulcer index, mucus secretion, oxidative stress and histopathological parameters, as compared with the individual agents. The developed system could completely revert the damage induced in ulcerated stomachs at physiological (ulcer index and mucus secretion), biochemical (oxidative stress) and histological levels.


CONCLUSIONS
This study establishes that suitable packaging of GE and Lactobacillus acidophilus together in floating beads can help exploit their prospects as therapeutic curative agents rather than potential preventive agents.
University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Study, Panjab University, Chandigarh, India.
Pramod Kumar
PK
Singh
Indu Pal
IP
Kaur
D000818:Animals; D000897:Anti-Ulcer Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001682:Biological Availability; D002396:Catechols / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004195:Disease Models, Animal; D016503:Drug Delivery Systems; D005233:Fatty Alcohols / Q000008:administration & dosage* / Q000493:pharmacokinetics; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects; D020939:Zingiber officinale; D007779:Lactobacillus acidophilus; D008863:Microspheres; D000081222:Monocyclic Sesquiterpenes; D010936:Plant Extracts / Q000008:administration & dosage*; D051381:Rats; D017208:Rats, Wistar; D012717:Sesquiterpenes / Q000008:administration & dosage* / Q000493:pharmacokinetics; D013270:Stomach / Q000187:drug effects; D013276:Stomach Ulcer / Q000188:drug therapy*; D058616:Synbiotics
D000897:Anti-Ulcer Agents; D002396:Catechols; D005233:Fatty Alcohols; D000081222:Monocyclic Sesquiterpenes; D010936:Plant Extracts; D012717:Sesquiterpenes; C477983:zingiberene; C007845:gingerol